IDH1 and glioblastoma: The most recent data from clinical trials treating newly diagnosed (90% IDH-wildtype, NCT03047473) and recurrent glioblastoma patients (63% IDH-wildtype, NCT03291314) in combination with AVE demonstrated no beneficial OS nor PFS.